GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Net Change in Cash

PRME (Prime Medicine) Net Change in Cash : $74.58 Mil (TTM As of Sep. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Prime Medicine Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Prime Medicine's Net Change in Cash for the three months ended in Sep. 2024 was $62.94 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 was $74.58 Mil.

Prime Medicine Net Change in Cash Historical Data

The historical data trend for Prime Medicine's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Prime Medicine Net Change in Cash Chart

Prime Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Net Change in Cash
28.33 161.57 2.57 -146.05

Prime Medicine Quarterly Data
Dec19 Dec20 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -76.62 -2.39 52.59 -38.56 62.94

Prime Medicine Net Change in Cash Calculation

Prime Medicine's Net Change in Cash for the fiscal year that ended in Dec. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-165.412+18.711+0.655+0
=-146.05

Prime Medicine's Net Change in Cash for the quarter that ended in Sep. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-25.912+50.342+38.513+0
=62.94

Net Change in Cash for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $74.58 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prime Medicine Net Change in Cash Related Terms

Thank you for viewing the detailed overview of Prime Medicine's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Prime Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Prime Medicine Inc (NAS:PRME) » Definitions » Net Change in Cash
Comparable Companies
RGNX IMTX KYMR SANA ADPT ETNB KURA CABA AMAM HLVX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
21 Erie Street, Cambridge, MA, USA, 02139
Website
https://www.primemedicine.com
Prime Medicine Inc is a biotechnology company committed to delivering genetic therapies to address diseases by deploying gene editing technology, Prime Editing. The Prime Editing technology is a next-generation technology that can search and replace to restore normal genetic function in the genome and can treat a wide spectrum of diseases with high unmet medical needs and efficient and broad gene editing technology.
Executives
Robert Nelsen director, 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners X, Llc 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Gv 2019 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Jeffrey D Marrazzo director 3737 MARKET STREET, SUITE 1300, PHILADELPHIA PA 19104
2019, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
Alphabet Inc. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2019 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PKWY, MOUNTAIN VIEW CA 94043
2021, L.p. Gv 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.l.c. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Gv 2021 Gp, L.p. 10 percent owner 1600 AMPHITHEATRE PARKWAY, MOUNTAIN VIEW CA 94043
Thomas Cahill director PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Keith Crandell 10 percent owner 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Carman Alenson officer: See Remarks 88 SIDNEY STREET, CAMBRIDGE MA 02139
Meredith Goldwasser officer: SVP, Strategy & Corporate Ops. PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139
Jeremy Duffield officer: Chief Scientific Officer PRIME MEDICINE, INC., 21 ERIE ST., CAMBRIDGE MA 02139